Fig. 3From: Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in JapanProportion of patients with a SDAI ≤ 3.3, and b CDAI ≤ 2.8. *p < 0.05; **p < 0.01 (vs placebo + MTX group). Two-sided Cochran-Mantel-Haenszel test. CDAI Clinical Disease Activity Index, MTX methotrexate, q2w every 2 weeks, SDAI, Simplified Disease Activity IndexBack to article page